S.E. Geller is G. William Arends Professor of Obstetrics and Gynecology and director, Center for Research on Women and Gender, University of Illinois at Chicago, Chicago, Illinois. A.R. Koch is senior research specialist, Center for Research on Women and Gender, University of Illinois at Chicago, Chicago, Illinois. P. Roesch is research specialist, Center for Research on Women and Gender, University of Illinois at Chicago, Chicago, Illinois. A. Filut is research assistant, Center for Women's Health Research, University of Wisconsin-Madison, Madison, Wisconsin. E. Hallgren is research assistant, Center for Research on Women and Gender, University of Illinois at Chicago, Chicago, Illinois. M. Carnes is professor of medicine, psychiatry, and industrial & systems engineering and director, Center for Women's Health Research, University of Wisconsin-Madison, Madison, Wisconsin.
Acad Med. 2018 Apr;93(4):630-635. doi: 10.1097/ACM.0000000000002027.
The National Institutes of Health (NIH) Revitalization Act of 1993 requires NIH-funded clinical trials to include women and minorities as participants and assess outcomes by sex and race or ethnicity. The objective of this study was to investigate current levels of compliance with these guidelines for inclusion, analysis, and reporting in NIH-funded randomized controlled trials (RCTs) and compare the results with those from 2009 and 2004, which the authors reported previously.
The authors identified 782 RCTs published in 14 leading U.S. medical journals in 2015 with a PubMed search. Of those, 142 were the primary report of an NIH-funded RCT, conducted in the United States, and eligible for analysis. The authors reviewed abstract, text, and tables of each eligible study as well as any follow-up published commentary to determine compliance with NIH guidelines.
Thirty-five studies limited enrollment to one sex. The median enrollment of women in the remaining 107 studies was 46%, but 16 (15.0%) enrolled less than 30% women. Twenty-eight of the 107 (26%) reported at least one outcome by sex or explicitly included sex as a covariate in statistical analysis. Of the 142 studies, 19 (13.4%) analyzed or reported outcomes by race or ethnicity. There were no statistically significant changes in inclusion, analysis, or reporting by sex, race, or ethnicity compared with the previous studies.
NIH policies have not resulted in significant increases in reporting results by sex, race, or ethnicity. The authors recommend strong journal policies to increase compliance with NIH policies.
1993 年《美国国立卫生研究院(NIH)复兴法案》要求 NIH 资助的临床试验将女性和少数族裔纳入参与者,并根据性别、种族或民族评估结果。本研究的目的是调查 NIH 资助的随机对照试验(RCT)中目前在纳入、分析和报告方面遵守这些指南的水平,并将结果与作者之前报告的 2009 年和 2004 年的结果进行比较。
作者通过 PubMed 搜索,确定了 2015 年在 14 种美国主要医学期刊上发表的 782 项 RCT,并对其中的 142 项作为 NIH 资助 RCT 的主要报告进行了分析,这些试验在美国进行,符合分析条件。作者回顾了每个符合条件的研究的摘要、文本和表格,以及任何已发表的后续评论,以确定其是否符合 NIH 指南。
35 项研究将入组限制在单一性别。其余 107 项研究中,女性的中位入组率为 46%,但有 16 项(15.0%)入组女性少于 30%。在 107 项研究中,有 28 项(26%)报告了至少一项按性别划分的结果,或在统计分析中明确将性别作为协变量。在 142 项研究中,有 19 项(13.4%)按种族或民族进行了分析或报告了结果。与之前的研究相比,在纳入、分析或报告性别、种族或民族方面没有统计学上的显著变化。
NIH 政策并未导致按性别、种族或民族报告结果的显著增加。作者建议期刊制定严格的政策,以提高对 NIH 政策的遵守。